The present invention relates to biocompatible microemulsion systems designed for controlled release drug delivery applications formulated with phospholipids such as lecithin (surfactant), a lipophilic additive (linker) containing 9 or more carbons in their alkyl group and hydrophilic-lipophilic balance (HLB) of 5 or less, and a surfactant-like hydrophilic additive (linker) containing between 6 to 9 carbon atoms in their alkyl tail. The combination of linkers and phospholipids produce formulations capable of delivering high concentrations of poorly soluble drugs into epithelial tissue using low surfactant concentrations, with minimum cytotoxic side effects.
Substituted mercapto acid amides, process for their preparation, pharmaceutical composition containing same and their use
申请人:Merck & Co., Inc.
公开号:EP0001989A1
公开(公告)日:1979-05-30
Substituted mercapto acid amides are prepared, and are useful as immunoregulants for correcting an imbalance of immune homeostasis, particularly as immunostimulants in the treatment of autoimmune and immune deficient diseases and disorders.
Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
申请人:Platform Brightworks Two, Ltd.
公开号:US10028949B2
公开(公告)日:2018-07-24
There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.
Compositions and methods for organ specific delivery of nucleic acids
申请人:The Board of Regents of the University of Texas System
公开号:US11229609B2
公开(公告)日:2022-01-25
The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.